Lung cancer in never-smokers: Beyond EGFR mutations and EGFR-TK inhibitors

ONCOLOGY

Volumn 24, Issue 1, 2010, Pages

  Burns, Timothy F ^a   Rudin, Charles M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HER; UNCLASSIFIED DRUG;

ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CARCINOGENESIS; CIGARETTE SMOKING; CLINICAL TRIAL; GENE AMPLIFICATION; GENE MUTATION; HISTOLOGY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UNITED STATES;

EID: 76149094491     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009.
2. Thun MJ, Henley SJ, Burns D, et al: Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst 98:691-699, 2006.
3. Rudin CM, Avila-Tang E, Harris CC, et al: Lung cancer in never smokers: Molecular profiles and therapeutic implications. Clin Cancer Res 15:5646-5661, 2009.
4. Tsao AS, Liu D, Lee JJ, et al: Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 106:2428-2436, 2006.
5. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009.
6. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004.
7. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346, 2005.
8. Riely GJ, Kris MG, Rosenbaum D, et al: Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14:5731-5734, 2008.